Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.42 |
| ▸ | ATP4B | P51164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | SPR | P35270 | 5/20 | 0.35 |
| ▸ | SLC8A1 | P32418 | 3/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417817 | 0.88 | ATP4A (0.46) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 | |
| SCHEMBL5989112 | 0.88 | ATP4A (0.46) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 | |
| SCHEMBL5414016 | 0.87 | ATP4A (0.41) | ATP4AATP4BCYP3A4CYP2C9SPR | |
| SCHEMBL5571082 | 0.86 | ATP4A (0.45) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 | |
| SCHEMBL5425463 | 0.86 | ATP4A (0.45) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 | |
| SCHEMBL6028182 | 0.86 | ATP4A (0.45) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 | |
| SCHEMBL5570682 | 0.85 | ATP4A (0.44) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 | |
| SCHEMBL5567363 | 0.85 | ATP4A (0.44) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 | |
| SCHEMBL5566450 | 0.85 | ATP4A (0.44) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 | |
| SCHEMBL5566826 | 0.85 | ATP4A (0.43) | ATP4AATP4BCYP3A4CYP2C9SLC8A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191334-A1 | Tricyclic imidazopyridines | ALTANA PHARMA AG (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1735318-A2 | 7H-8,9-DIHYDRO-PYRANO(2,3-C)IMIDAZO(1,2A)PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005090358-A2 | 7H-8,9-DIHYDRO-PYRANO (2,3-C) IMIDAZO (1,2A) PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191334-A1 | Tricyclic imidazopyridines | GIPR, SLC10A2, MLNR | ATP4A 131/4885ATP4B 510/4885CYP3A4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.